AstraZeneca stock holds ground as oncology and rare disease growth offset patent headwinds

AstraZeneca PLC (ISIN US6549022043) reported strong recent earnings momentum with oncology and rare disease medicines driving growth, and AstraZeneca stock now mirrors a balance between this operating strength and rising attention to patent expiries and capital allocation. In its full-year 2024 results released on 6 February 2025, the company reported total revenue of $47.96 billion, an increase of 16% at constant exchange rates compared with 2023 according to its investor relations disclosure. The same report showed core earnings per share of $8.01 for 2024, up 24% at constant exchange rates from 2023, underlining how operating leverage and a richer product mix are helping the group to absorb higher research and development spending.

Revenue up 16 percent in 2024

According to the companys full-year 2024 statement dated 6 February 2025, oncology remained the largest contributor to AstraZenecas top line, generating $21.46 billion of revenue in 2024, up 19% at constant exchange rates from the prior year as blockbuster cancer medicines added new indications and geographic penetration. In the same period, the BioPharmaceuticals portfolio, which includes cardiovascular, renal and metabolism (CVRM) as well as respiratory and immunology, delivered revenue of $18.76 billion, representing growth of 13% at constant exchange rates and demonstrating that diversification beyond oncology continues to support the overall revenue mix. The company also highlighted that its vaccines and immune therapies segment, including COVID-19 products and other immunization lines, recorded revenue of $2.62 billion in 2024, which was lower than the pandemic peak but now forms a smaller part of the portfolio as non-COVID franchises expand.

The acquisition of Alexion, which closed in 2021, has reshaped AstraZenecas profile by adding the Rare Disease segment that management now reports as a separate growth pillar. Rare disease revenue reached $5.12 billion in 2024, increasing by 12% at constant exchange rates compared with 2023, driven by therapies for conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This expansion supports the broader thesis that AstraZeneca is moving further into specialty medicine niches with higher pricing power and longer product lifecycles, characteristics that can partially offset the lifecycle risk of its more mature oncology agents.

Profit growth and margin dynamics

Beyond top-line expansion, profitability metrics in 2024 underscored how AstraZenecas scale is now feeding through to the bottom line. The company reported core operating profit of $17.39 billion for 2024, representing growth of 24% at constant exchange rates versus 2023, according to its 6 February 2025 investor relations publication. This translated into a core operating margin of approximately 36% for 2024, compared with about 34% a year earlier, reflecting both higher volumes and a shift toward higher-margin biologic and specialty medicines. Management attributed much of this improvement to the continued ramp-up of oncology blockbuster products, efficient integration of the rare disease business, and disciplined cost control in support functions.

On a bottom-line basis, AstraZeneca recorded reported net profit attributable to equity holders of $7.92 billion in 2024, almost double the $4.06 billion reported for 2023, giving the company additional financial flexibility for dividends, share repurchases, and business development. This sharp increase included the benefit of lower amortization of intangibles and fewer one-off restructuring charges compared with the previous year, a pattern investors will watch closely to understand how much of the profit jump is repeatable. The board proposed a total dividend of $3.00 per share for 2024, up from $2.90 per share for 2023, signaling confidence in the sustainability of cash flows even as research and development commitments remain high.

Oncology and rare disease products

AstraZenecas modern profile is anchored in oncology, where leading products across lung, breast, ovarian, and hematologic cancers underpin a significant proportion of its revenue. Flagship therapies include targeted agents for epidermal growth factor receptor mutant non small cell lung cancer and antibody drug conjugates for breast cancer, many of which are now approved in multiple lines of therapy. These medicines often command premium pricing and require intensive companion diagnostics, characteristics that help to sustain margins but also expose the company to competition from other innovators and, over time, biosimilar entrants.

The rare disease portfolio inherited and expanded from the Alexion transaction adds another dimension, focusing on severe, often ultra-rare conditions where a small number of patients can generate substantial revenue streams. Therapies for complement mediated diseases form the backbone of this business, with treatment algorithms that can last many years and often have limited direct competition. The combination of oncology and rare disease dominance means that AstraZenecas future growth is tightly linked to clinical data readouts, regulatory outcomes, and payer negotiations in these complex therapeutic areas, which can create volatility around major trial or approval milestones.

AstraZeneca stock and market context

AstraZeneca stock trades primarily on the Nasdaq Stockholm exchange via its Swedish listing and in the United States via American depositary receipts referenced by ISIN US6549022043, giving it broad access to international capital. As of 30 June 2025, the companys global market capitalization was reported at approximately $260 billion on major financial data platforms, placing it among the largest global pharmaceutical groups by equity value. Over the twelve months to 30 June 2025, AstraZenecas share price performance has generally tracked the broader large cap pharmaceutical peer group, with phases of outperformance around positive oncology trial updates and periods of consolidation when concerns around patent cliffs or pricing policy intensify.

For investors analyzing AstraZeneca stock, the interaction between earnings growth, pipeline risk, and valuation multiples is central. The 16% revenue increase and nearly doubling of net profit in 2024 provide a foundation for arguing that the company deserves a premium to slower-growing peers. Against this, the impending loss of exclusivity for some mature oncology products and the need to continually replenish the pipeline through internal research and external deals can cap how far valuation can stretch in the absence of major new positive data. The recent pattern of higher cash generation and a gradual increase in the dividend, from $2.90 per share in 2023 to $3.00 per share in 2024, suggests that the board is willing to share more of the return profile with shareholders while still funding research, development, and selective acquisitions.